In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PE Catches Third Wave

Executive Summary

PE Biosystems Group now controls about 43% of the worldwide market for DNA sequencing, sequence detection, and protein analysis. It's a position worth protecting--it was clearly a major contributor to the $1.2 billion in sales generated by PE Biosystems in 1999. The group obviously has a lot riding on PCR. Little wonder, then, that it has made a practice of actively working with emerging companies and emerging technologies that could complement its own vital technology--or perhaps, displace it. The company would lose a fortune if a competing technology somehow obviated PCR…unless, of course, PE Biosystems could absorb that contender. It appears that PE has made just such a strategic acquisition, to protect its position as the market leader. On January 24th, PE Biosystems said it would acquire Third Wave Technologies Inc. of Madison, Wisconsin, in a stock-for-stock transaction that values the small private firm founded in 1993 at a hefty $287.7 million.

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts